MedTrace Logo

Study of GTx-024 on Muscle Wasting (Cachexia) Cancer.

NCT00467844 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 159

Last updated 2014-07-11

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to assess if Gtx-024 is effective in increasing lean body mass in subjects with muscle wasting related to cancer.

Conditions

  • Cachexia

Interventions

DRUG

GTx-024

1 mg GTx 024

DRUG

GTx-024

3 mg GTx-024

DRUG

Placebo

Matching Placebo

Sponsors & Collaborators

  • GTx

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
SUPPORTIVE_CARE
Masking
QUADRUPLE
Model
PARALLEL

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-05-31
Primary Completion
2008-09-30
Completion
2008-09-30

Countries

  • United States
  • Canada

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00467844 on ClinicalTrials.gov